enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Pomalidomide - Wikipedia

    en.wikipedia.org/wiki/Pomalidomide

    Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]

  3. Cereblon E3 ligase modulator - Wikipedia

    en.wikipedia.org/wiki/Cereblon_E3_ligase_modulator

    The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.

  4. Pomalyst Takes the Stage - AOL

    www.aol.com/news/2013-02-21-pomalyst-takes-the...

    The answer is Pomalyst -- Celgene's most recently approved drug. In previous articles in this series, we reviewed the company's other drugs currently on the market -- Revlimid , Vidaza , Thalomid ...

  5. Lenalidomide - Wikipedia

    en.wikipedia.org/wiki/Lenalidomide

    Severe side effects include low blood platelets, low white blood cells, and blood clots. [8] The dose may need to be adjusted in people with kidney problems. [8] Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus. [8]

  6. Medicare caps seniors drug expenses: What you need to know - AOL

    www.aol.com/news/medicare-caps-seniors-drug...

    Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis.

  7. Celgene's Multiple Myeloma Powerhouse - AOL

    www.aol.com/news/2013-08-22-celgenes-multiple...

    Earlier this month, biotech powerhouse Celgene announced that the European Commission approved the combinational therapy of pomalidomide, known in the United States as Pomalyst, and dexamethasone ...

  8. More Good News for Celgene - AOL

    www.aol.com/news/2013-02-11-more-good-news-for...

    As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene's Pomalyst in treating patients with multiple myeloma. Patients must have received at least two prior ...

  9. Elotuzumab - Wikipedia

    en.wikipedia.org/wiki/Elotuzumab

    Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. [3]